rss
Ann Rheum Dis 70:1511-1512 doi:10.1136/ard.2010.143438
  • Letters

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis

  1. Giampaolo Merlini1
  1. 1Amyloidosis Research and Treatment Center, Biotechnology Research Laboratories and Department of Biochemistry, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
  2. 2Immuno-Rheumatology Unit, Clinica Pediatrica, University of Brescia, Brescia, Italy
  3. 3Nephrology Unit, Ospedale Sandro Pertini, Roma, Italy
  1. Correspondence to Professor Giampaolo Merlini, Amyloid Research and Treatment Center, Biotechnology Research Laboratories, Fondazione IRCCS Policlinico San Matteo Viale Golgi, 19, 27100 Pavia, Italy; gmerlini{at}unipv.it
  • Accepted 11 November 2010
  • Published Online First 20 December 2010

Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) is a dominantly inherited autoinflammatory disease characterised by recurrent episodes of fever, arthritis and serositis. In adulthood, inflammation often becomes persistent1 and AA amyloidosis may occur. Evidence of dysregulated secretion of proinflammatory cytokines, particularly interleukin 1 (IL-1) beta, in autoinflammatory diseases recently supported anakinra, the recombinant IL-1 receptor antagonist, as a target therapy for most of these conditions.2 3 In TRAPS, response to anakinra was reported in two case reports and in one prospective trial, in which five patients were treated for a mean duration of 11.4 months.4,,6 However, longer follow-up and additional observations are warranted. We report the long-term efficacy and safety of anakinra in seven TRAPS patients with and without …

Free sample This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article